Live Breaking News & Updates on Metagenomi inc

Stay informed with the latest breaking news from Metagenomi inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Metagenomi inc and stay connected to the pulse of your community

Healthy Returns: Biotech IPOs heated up, but haven't fully recovered

Biotech IPOs surged at the start of 2024, but the rest of the year will depend on Fed rate cuts. Meanwhile, doctors using VR and AI to hone their skills.

Mike-perrone , Arrivent-biopharma , Federal-reserve , Fractyl-health , Telomir-pharmaceuticals , Biopharma-dive , Vent-biopharma , Contineum-therapeutics , Arda-ural , Biotech-and-pharmaceuticals , Health-care-industry , Unitedhealth-group-inc

Metagenomi to Present at Upcoming Scientific Meetings

- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will prese

Spain , Madrid , Nasdaq , American-society-of-gene-cell-therapy , Metagenomi-inc , Oral-presentation-at-world-federation-of-hemophilia , World-federation-of-hemophilia , World-congress , World-federation , American-society , Cell-therapy

Brokerages Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $21.40

Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) has earned an average rating of “Buy” from the six ratings firms that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $21.40. […]

United-states , Jpmorgan-chase-co , Metagenomi-inc , Holdingsas-novo , Wells-fargo-company , Nasdaq , Metagenomi-company-profile , Get-free-report , Trading-down , Get-free , Metagenomi-daily

Metagenomi, Inc. Expected to Earn FY2024 Earnings of ($2.44) Per Share (NASDAQ:MGX)

Metagenomi, Inc. (NASDAQ:MGX – Free Report) – Chardan Capital issued their FY2024 earnings estimates for Metagenomi in a note issued to investors on Monday, April 1st. Chardan Capital analyst G. Livshits forecasts that the company will post earnings per share of ($2.44) for the year. Chardan Capital currently has a “Buy” rating and a $21.00 […]

United-states , Nasdaq , Wells-fargo-company , Metagenomi-inc , Jpmorgan-chase-co , Jefferies-financial-group , Holdingsas-novo , Free-report , Chardan-capital , Get-free-report , Metagenomi-daily

Moderna (NASDAQ:MRNA) versus Cardiol Therapeutics (NASDAQ:CRDL) Head to Head Analysis

Moderna (NASDAQ:MRNA – Get Free Report) and Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Institutional and Insider Ownership 75.3% of Moderna shares are […]

Canada , Cambridge , Cambridgeshire , United-kingdom , Oakville , Ontario , Massachusetts , United-states , Chiesi-farmaceutici , Institute-for-life-changing-medicines , Cardiol-therapeutics-inc , Moderna-inc

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of...

Brianc-thomas , Sarah-noonberg , Luis-borges , Simon-harnest , Pamela-wapnick , Ashlye-hodge , Metagenomi-inc , Securities-exchange , Technology-platform , Nasdaq , Development-candidate

Metagenomi Reports Business Updates and Full Year 2023

Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman...

Sarah-noonberg , Luis-borges , Pamela-wapnick , Ashlye-hodge , Simon-harnest , Brianc-thomas , Technology-platform , Nasdaq , Metagenomi-inc , Securities-exchange , Development-candidate

Metagenomi (NASDAQ:MGX) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Metagenomi (NASDAQ:MGX – Free Report) in a research report sent to investors on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $16.00 price target on the stock. MGX has been the topic of several other research reports. Jefferies Financial Group started coverage on […]

United-states , Jefferies-financial-group , Metagenomi-inc , Securities-exchange-commission , Wells-fargo-company , Metagenomi-company-profile , Holdingsas-novo , Nasdaq , Jpmorgan-chase-co , Free-report , Financial-group

Metagenomi (NASDAQ:MGX) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Metagenomi (NASDAQ:MGX – Free Report) in a report released on Tuesday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $25.00 target price on the stock. Metagenomi Price Performance MGX stock opened at $11.78 on Tuesday. Metagenomi has a 12-month low of $9.74 and […]

United-states , Metagenomi-inc , Holdingsas-novo , Securities-exchange-commission , Wells-fargo-company , Metagenomi-company-profile , Wells-fargo , Free-report , Exchange-commission , Get-free-report , Metagenomi-daily

BMO Capital Markets Initiates Coverage on Metagenomi (NASDAQ:MGX)

BMO Capital Markets initiated coverage on shares of Metagenomi (NASDAQ:MGX – Free Report) in a research report released on Tuesday, MarketBeat reports. The firm issued an outperform rating and a $22.00 price target on the stock. MGX has been the topic of a number of other reports. Wells Fargo & Company initiated coverage on shares […]

United-states , Securities-exchange-commission , Metagenomi-inc , Jefferies-financial-group , Metagenomi-company-profile , Wells-fargo-company , Jpmorgan-chase-co , Holdingsas-novo , Free-report , Stock-down , Exchange-commission